[HTML][HTML] Epidermal growth factor receptor in non-small cell lung cancer
CN Prabhakar - Translational lung cancer research, 2015 - ncbi.nlm.nih.gov
Following the identification of a group of patients in the initial tyrosine kinase inhibitor (TKI)
trials for lung cancer, there has been detailed focus on which patients may benefit from …
trials for lung cancer, there has been detailed focus on which patients may benefit from …
[HTML][HTML] Uncommon EGFR mutations in non-small-cell lung cancer: A systematic literature review of prevalence and clinical outcomes
T John, A Taylor, H Wang, C Eichinger, C Freeman… - Cancer …, 2022 - Elsevier
Mutations in exons 18–21 of the epidermal growth factor receptor gene (EGFR) can confer
sensitivity to EGFR-tyrosine kinase inhibitors (EGFR-TKIs) in patients with non-small-cell …
sensitivity to EGFR-tyrosine kinase inhibitors (EGFR-TKIs) in patients with non-small-cell …
Combination of gefitinib and DNA methylation inhibitor decitabine exerts synergistic anti-cancer activity in colon cancer cells
Y Lou, Z Zou, P Chen, G Huang, B Li, D Zheng, X Yu… - PloS one, 2014 - journals.plos.org
Despite recent advances in the treatment of human colon cancer, the chemotherapy efficacy
against colon cancer is still unsatisfactory. In the present study, effects of concomitant …
against colon cancer is still unsatisfactory. In the present study, effects of concomitant …
Analysis of CEA expression and EGFR mutation status in non-small cell lung cancers
ZM Yang, XP Ding, L Pen, L Mei… - Asian Pacific Journal of …, 2014 - koreascience.kr
Background: The serum carcinoembryonic antigen (CEA) level can reflect tumor growth,
recurrence and metastasis. It has been reported that epidermal growth factor receptor …
recurrence and metastasis. It has been reported that epidermal growth factor receptor …
Role of HGF–MET signaling in primary and acquired resistance to targeted therapies in cancer
The Hepatocyte growth factor (HGF)—mesenchymal-epithelial transition (MET) pathway is
deregulated in several cancers and is associated with aggressive phenotype and worse …
deregulated in several cancers and is associated with aggressive phenotype and worse …
[HTML][HTML] Comparing overall survival between first generation EGFR-TKIs and chemotherapy in lung cancer patients with Del19/L858R
W Deng, Y Lei, S Liu, J Yang, H Tu… - Chinese Journal of …, 2016 - ncbi.nlm.nih.gov
Objective Combined overall survival (OS) analysis of Lux-Lung 3 and Lux-Lung 6
demonstrated that patients with epidermal growth factor receptor (EGFR) exon 19 deletions …
demonstrated that patients with epidermal growth factor receptor (EGFR) exon 19 deletions …
Monitoring of high-density lipoprotein cholesterol level is predictive of EGFR mutation and efficacy of EGFR-TKI in patients with advanced lung adenocarcinoma
Y Lv, LY Miao, QF Chen, Y Li, ZX Shi… - OncoTargets and …, 2016 - Taylor & Francis
High-density lipoprotein cholesterol (HDL-C) has an inverse association with the incidence
of lung cancer. However, whether it can be used as a predictive factor in advanced lung …
of lung cancer. However, whether it can be used as a predictive factor in advanced lung …
Exploratory cohort study and meta-analysis of BIM deletion polymorphism in patients with epidermal growth factor receptor-mutant non-small-cell lung cancer treated …
S Sun, H Yu, H Wang, X Zhao, X Zhao, X Wu… - OncoTargets and …, 2017 - Taylor & Francis
Background Non-small-cell lung cancer (NSCLC) patients with epidermal growth factor
receptor (EGFR) mutations might develop primary and secondary resistance to tyrosine …
receptor (EGFR) mutations might develop primary and secondary resistance to tyrosine …
A Prospective Observational Study Evaluating the Correlation of c-MET Expression and EGFR Gene Mutation with Response to Erlotinib as Second-Line Treatment …
CK Park, IJ Oh, YD Choi, TW Jang, JE Lee, JS Ryu… - Oncology, 2018 - karger.com
Objectives: We aimed to evaluate the prevalence and predictive role of c-MET expression
and EGFR mutation in the efficacy of erlotinib in non-small-cell lung cancer (NSCLC) …
and EGFR mutation in the efficacy of erlotinib in non-small-cell lung cancer (NSCLC) …
Transcriptomic Analysis Reveals Early Alterations Associated with Intrinsic Resistance to Target Therapy in Lung Adenocarcinoma Cell Lines
M Perez-Medina, JS Lopez-Gonzalez, JJ Benito-Lopez… - 2024 - preprints.org
Lung adenocarcinoma is the most prevalent form of lung cancer, and drug resistance is a
significant obstacle in its treatment. This study aimed to investigate the overexpression of …
significant obstacle in its treatment. This study aimed to investigate the overexpression of …